Breast Cancer Clinical Trials in Beijing
15 recruitingBeijing, China
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Breast Cancer
AstraZeneca100 enrolled40 locationsNCT07205822
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
Not Applicable
A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
Breast CancerAblation
Peking University People's Hospital200 enrolled1 locationNCT07238894
Recruiting
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd400 enrolled87 locationsNCT06079983
Recruiting
Phase 3
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd339 enrolled1 locationNCT06313983
Recruiting
Not Applicable
Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy
Breast Cancer
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06909604
Recruiting
Phase 2
Hypofractionated Online Adaptive Radiotherapy of Breast Cancer
Breast Cancer
Peking Union Medical College Hospital40 enrolled1 locationNCT06568705
Recruiting
Early Phase 1
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Breast CancerProstate CancerBrain Tumor+1 more
Peking Union Medical College Hospital90 enrolled1 locationNCT05549024
Recruiting
Phase 2
Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
Breast CancerRadiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences65 enrolled1 locationNCT05762900
Recruiting
Phase 3
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Breast Cancer
Peking University234 enrolled1 locationNCT02535221